Emilia M. Pulver

Emilia M. Pulver

Auto-generated profile, based on publicly available information

Emilia M. Pulver

Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JHJulia M. Houthuijzen
Julia M. Houthuijzen
RBRoebi de Bruijn
Roebi de Bruijn
EBEline van der Burg
Eline van der Burg
ADAnne Paulien Drenth
Anne Paulien Drenth
EWEllen Wientjens
Ellen Wientjens
JJJos Jonkers
Jos Jonkers
Cancer-associated fibroblasts (CAFs) are abundantly present in the microenvironment of virtually all tumors and strongly impact tumor progression. Despite increasing insight into their function and heterogeneity, little is known regarding the origin of CAFs. Understanding the origin of CAF heterogeneity is needed to develop successful CAF-based targeted therapies. Through various transplantation studies in mice, we show that CAFs in both invasive lobular breast cancer and triple-negative breast cancer originate from mammary tissue-resident normal fibroblasts (NFs). Single-cell transcriptomics, in vivo and in vitro studies reveal the transition of CD26+ and CD26- NF populations into inflammatory CAFs (iCAFs) and myofibroblastic CAFs (myCAFs), respectively. Functional co-culture experiments show that CD26+ NFs transition into pro-tumorigenic iCAFs which recruit myeloid cells in a CXCL12-dependent manner and enhance tumor cell invasion via matrix-metalloproteinase (MMP) activity. Together, our data suggest that CD26+ and CD26- NFs transform into distinct CAF subpopulations in mouse models of breast cancer.

21 September 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
EPEmilia M. Pulver
Emilia M. Pulver
CMChirantani Mukherjee
Chirantani Mukherjee
GKGerarda van de Kamp
Gerarda van de Kamp
SRStefan J. Roobol
Stefan J. Roobol
MRMagdalena B. Rother
Magdalena B. Rother
JJJos Jonkers
Jos Jonkers
The BRCA1 tumor suppressor gene encodes a multidomain protein for which several functions have been described. These include a key role in homologous recombination repair (HRR) of DNA double-strand breaks, which is shared with two other high-risk hereditary breast cancer suppressors, BRCA2 and PALB2. Although both BRCA1 and BRCA2 interact with PALB2, BRCA1 missense variants affecting its PALB2-interacting coiled-coil domain are considered variants of uncertain clinical significance (VUS). Using genetically engineered mice, we show here that a BRCA1 coiled-coil domain VUS, Brca1 p.L1363P, disrupts the interaction with PALB2 and leads to embryonic lethality. Brca1 p.L1363P led to a similar acceleration in the development of Trp53-deficient mammary tumors as Brca1 loss, but the tumors showed distinct histopathologic features, with more stable DNA copy number profiles in Brca1 p.L1363P tumors. Nevertheless, Brca1 p.L1363P mammary tumors were HRR incompetent and responsive to cisplatin and PARP inhibition. Overall, these results provide the first direct evidence that a BRCA1 missense variant outside of the RING and BRCT domains increases the risk of breast cancer. Significance: These findings reveal the importance of a patient-derived BRCA1 coiled-coil domain sequence variant in embryonic development, mammary tumor suppression, and therapy response. See related commentary by Mishra et al., p. 6080

31 March 2023
Verified
Other
Open access
EPEmilia M. Pulver
Emilia M. Pulver
CMChirantani Mukherjee
Chirantani Mukherjee
GKGerarda van de Kamp
Gerarda van de Kamp
SRStefan J. Roobol
Stefan J. Roobol
MRMagdalena B. Rother
Magdalena B. Rother
JJJos Jonkers
Jos Jonkers
The BRCA1 tumor suppressor gene encodes a multidomain protein for which several functions have been described. These include a key role in homologous recombination repair (HRR) of DNA double-strand breaks, which is shared with two other high-risk hereditary breast cancer suppressors, BRCA2 and PALB2. Although both BRCA1 and BRCA2 interact with PALB2, BRCA1 missense variants affecting its PALB2-interacting coiled-coil domain are considered variants of uncertain clinical significance (VUS). Using genetically engineered mice, we show here that a BRCA1 coiled-coil domain VUS, Brca1 p.L1363P, disrupts the interaction with PALB2 and leads to embryonic lethality. Brca1 p.L1363P led to a similar acceleration in the development of Trp53-deficient mammary tumors as Brca1 loss, but the tumors showed distinct histopathologic features, with more stable DNA copy number profiles in Brca1 p.L1363P tumors. Nevertheless, Brca1 p.L1363P mammary tumors were HRR incompetent and responsive to cisplatin and PARP inhibition. Overall, these results provide the first direct evidence that a BRCA1 missense variant outside of the RING and BRCT domains increases the risk of breast cancer.Significance:These findings reveal the importance of a patient-derived BRCA1 coiled-coil domain sequence variant in embryonic development, mammary tumor suppression, and therapy response.See related commentary by Mishra et al., p. 6080

3 April 2023
Verified
Other
Open access
JLJustin H. Lo
Justin H. Lo
LHLiang Hao
Liang Hao
MMMandar D. Muzumdar
Mandar D. Muzumdar
SRSrivatsan Raghavan
Srivatsan Raghavan
EKEster J. Kwon
Ester J. Kwon
SBSangeeta N. Bhatia
Sangeeta N. Bhatia
Figure S1. In vitro optimization of iRGD TPNs in PDAC cell lines; Figure S2. Dual knockdown using TPNs; Figure S3. In vitro and in vivo properties and function of PEGylated iRGD TPNs; Figure S4. Overview of organoid image analysis; Figure S5. iRGD TPN-mediated delivery of siRNA in models of pancreatic cancer; Figure S6. iRGD-mediated TPN uptake and NRP-1 expression in the tumor vasculature; Figure S7. Stromal elements in a KPC-derived orthotopic tumor section following iRGD TPN administration.

31 March 2023
Verified
Other
Open access
EPEmilia M. Pulver
Emilia M. Pulver
CMChirantani Mukherjee
Chirantani Mukherjee
GKGerarda van de Kamp
Gerarda van de Kamp
SRStefan J. Roobol
Stefan J. Roobol
MRMagdalena B. Rother
Magdalena B. Rother
JJJos Jonkers
Jos Jonkers
Included are the supplementary methods, tables, and figures.

31 March 2023
Verified
Other
Open access
EPEmilia M. Pulver
Emilia M. Pulver
CMChirantani Mukherjee
Chirantani Mukherjee
GKGerarda van de Kamp
Gerarda van de Kamp
SRStefan J. Roobol
Stefan J. Roobol
MRMagdalena B. Rother
Magdalena B. Rother
JJJos Jonkers
Jos Jonkers
Included are the supplementary methods, tables, and figures.